HEDRICK MARC H 4

What Happened Marc H. Hedrick, CEO of Plus Therapeutics, was granted two equity-based awards on February 25, 2026. Each award covers 2,419,582 derivative shares (totaling 4,839,164). Both grants were recorded at $0.00 acquisition price (typical for compensation awards) and are derivative instruments rather than immediately issued common stock.

Key Details

• Transaction date: 2026-02-25; Form filed 2026-02-27 (appears timely).
• Grant type/code: A = Award/Grant; reported as derivative securities.
• Quantities: 2,419,582 + 2,419,582 = 4,839,164 derivative shares granted.
• Price: $0.00 per share at grant (no cash paid).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes:
  • F1 (RSUs): Each Restricted Stock Unit = contingent right to one share; RSUs vest ratably over 12 quarters in equal 1/12 increments, beginning with 1/12 vesting on April 1, 2026.
  • F2 (option-like award): Vests over four years in equal 1/48 monthly increments and accelerates on a change of control per the employment agreement.

Context

• These are compensation awards (RSUs and option-style grants), not open-market purchases or sales. RSUs convert to actual shares as they vest; option-style awards require vesting (and possibly exercise) before becoming owned shares.
• Such grants are commonly used for retention and incentive; they do not by themselves indicate immediate buying or selling of company stock.